# US 2006/0233861 A1 · Modulation of atp production or content in the hypothalamus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0233861 A1
- Document ID: US20060233861A1
- Status: Published application
- Kind: A1
- Application number: 10/545,677
- Filed: 2004-02-16
- Published: 2006-10-19
- Earliest claimed: 2003-02-14
- Inventors: David Maclean
- Web page: https://patentgrep.com/patent/US20060233861A1

## CPC

- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 36/27: Asclepiadaceae (Milkweed family), e.g. hoya
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- G01N 33/743: {Steroid hormones}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for the identification of agents for use in the treatment of metabolic diseases, disorders or conditions, for example obesity and diabetes, or for causing weight loss without substantial adverse health effects, in an animal in need of such treatment, comprises the step of identifying an agent that modulates ATP production or content in the hypothalamus of an animal.

## Claims

### Claim 1

A method for the identification of agents for use in the treatment of metabolic diseases, disorders or conditions in an animal in need of such treatment, comprising the step of identifying an agent that modulates ATP production or content in the hypothalamus of the animal.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the metabolic disease, disorder or condition is an appetitive disease, disorder or condition.

### Claim 3 (depends on 2)

A method according to claim 2, wherein the metabolic disease, disorder or condition is obesity.

### Claim 4 (depends on 2)

A method according to claim 2, wherein the metabolic disease, disorder or condition is diabetes.

### Claim 5

A method comprising the step of identifying an agent that modulates ATP production or content in the hypothalamus of the animal, wherein said method identified agents that:
a. regulate food-intake or calorific-intake in the animal, or
b. decrease food-intake or calorific-intake in an animal, or
c. cause body mass reduction in an animal without substantial adverse health effects, or
d. aid in the treatment of diabetes in an animal in need of such treatment.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8 (depends on 5)

A method according to claim 5, wherein the agent increases ATP production or content in the hypothalamus of the animal.

### Claim 9

A method for the identification of agents for use in the treatment of diabetes in an animal in need of such treatment, comprising the step of identifying an agent that modulates ATP production or content in the hypothalamus of the animal.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

A method according to claim 1, further including the step, after identification of an agent that modulates ATP production or content in the hypothalamus of an animal, of identifying a source of the agent.

### Claim 12 (depends on 11)

A method according to claim 11, wherein the source is a plant or a plant extract.

### Claim 13 (depends on 11)

A method according to claim 11, wherein the source is a synthetically produced agent.

### Claim 14 (depends on 1)

A method according to claim 1, wherein the agent is a steroidal glycoside.

### Claim 15 (depends on 14)

A method according to claim 14, wherein the steroidal glycoside comprises a mono- or poly-saccharide moiety at the 3-O position of the steroid ring system.

### Claim 16 (depends on 15)

A method according to claim 15, wherein the mono- or poly-saccharide moiety is a trisaccharide comprising 6-deoxy and/or 2,6-dideoxy hexoses.

### Claim 17 (depends on 16)

A method according to claim 16, wherein the terminal saccharide of the mono- or poly-saccharide moiety is thevetosyl.

### Claim 18 (depends on 14)

A method according to claim 14, wherein the steroidal glycoside comprises an ester moiety at the 12 position of the steroid ring system.

### Claim 19 (depends on 18)

A method according to claim 18, wherein the ester is benzoyl, tigloyl or anthraninoyl.

### Claim 20 (depends on 1)

A method according to claim 1, further including the step, after identifying the source of the agent, of providing the source of the agent as a substance adapted for administration to the animal.

### Claim 21 (depends on 20)

A method according to claim 20, wherein the substance is fresh, dried or otherwise preserved plant material.

### Claim 22 (depends on 20)

A method according to claim 20, wherein the substance is an isolated and/or purified plant extract.

### Claim 23 (depends on 20)

A method according to claim 20, wherein the substance is a pharmaceutical composition.

### Claim 24 (depends on 20)

A method according to claim 20, wherein the substance is a foodstuff or food additive.

### Claim 25 (depends on 20)

A method according to claim 20, wherein the substance is a beverage or beverage additive.

### Claim 26

A method for treating a metabolic disease, disorder or condition in an animal in need of such treatment, comprising administering a therapeutically effective amount of an agent known through scientific research to modulate ATP production or content in the hypothalamus of the animal, and for the purpose of knowingly modulating ATP production or content in the hypothalamus of the animal.

### Claim 27

A pharmaceutical composition comprising a therapeutically effective amount of an agent known through scientific research to modulate ATP production or content in the hypothalamus of an animal, wherein said composition is a-medicament for treating a metabolic disease, disorder or condition in the animal in need of such treatment by knowingly modulating ATP production or content in the hypothalamus of the animal.

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

A method for causing body mass reduction in an animal without substantial adverse health effects, comprising administering a therapeutically effective amount of an agent known through scientific research to modulate ATP production or content in the hypothalamus of the animal, and for the purpose of knowingly modulating ATP production or content in the hypothalamus of the animal.

### Claim 33

A pharmaceutical composition comprising a therapeutically effective amount of an agent known through scientific research to modulate ATP production or content in the hypothalamus of an animal, wherein said composition is a medicament for causing body mass reduction in the animal without substantial adverse health effects by knowingly modulating ATP production or content in the hypothalamus of the animal.

### Claim 34

A substance adapted for administration to an animal and intended to treat metabolic diseases, disorders and conditions in the animal or to cause weight loss in the animal without substantial adverse health effects, the substance comprising a therapeutically effective amount of an agent known through scientific research to modulate the production or content of ATP in the hypothalamus of the animal, optionally in association with a pharmaceutically acceptable or dietetic excipient, diluent or carrier, or a foodstuff or beverage.

### Claim 35 (depends on 34)

A substance according to claim 34, wherein the agent is provided as fresh or preserved plant material containing the agent.

### Claim 36 (depends on 34)

A substance according to claim 34, wherein the agent is provided as a plant extract consisting of or containing the agent.

### Claim 37 (depends on 34)

A substance according to claim 34, wherein the agent is provided as a synthetic chemical compound or mixture of compounds.

### Claim 38 (depends on 34)

A substance according to claim 34, when present with packaging and/or other written material describing the use and the activity of the agent in modulating the production or content of ATP in the hypothalamus.

### Claim 39 (depends on 26)

A method according to claim 26, wherein the agent is a steroidal glycoside.

### Claim 40 (depends on 27)

A pharmaceutical composition according to claim 27, wherein the agent is a steroidal glycoside.

### Claim 41 (depends on 34)

A substance according to claim 34, wherein the agent is a steroidal glycoside.

### Claim 42 (depends on 26)

A method according to claim 26, wherein the disease, disorder or condition to be treated, or the physiological effect to be caused, is an appetitive disease, disorder or condition.

### Claim 43 (depends on 27)

A pharmaceutical composition according to claim 27, wherein the disease, disorder or condition to be treated, or the physiological effect to be caused, is an appetitive diseases disorder or condition.

### Claim 44 (depends on 34)

A substance according to claim 34, wherein the disease, disorder or condition to be treated, or the physiological effect to be caused, is an appetitive disease, disorder or condition.

### Claim 45

A method for the identification of agents for use in the treatment of appetitive diseases, disorders, or conditions in an animal comprising the step of identifying an agent that modulates ATP production in the hypothalamus of said animal.

### Claim 46

A method for the identification of agents that regulate food-intake in an animal comprising the step of identifying an agent that modulates ATP production in the hypothalamus of said animal.

### Claim 47 (depends on 46)

The method of claim 46, wherein the regulation of food-intake is a decrease in food-intake.

### Claim 48

A method for the identification of agents for use in the treatment of diabetes in an animal comprising the step of identifying an agent that increases ATP production or content in the hypothalamus of said animal.

### Claim 49

A method for treating an appetitive disease, disorder, or condition comprising the step of administering to an animal in need of such treatment a therapeutically effective amount of an agent that modulates ATP production in the hypothalamus of an animal, provided that said agent is not an extract from a plant of the genus Trichocaulon or Hoodia.

### Claim 50

(canceled)

### Claim 51

A method for treating diabetes comprising the step of administering to an animal in need of such treatment a therapeutically effective amount of an agent that increases ATP production or content in the hypothalamus of an animal, provided that said agent is not an extract from a plant of the genus Trichocaulon or Hoodia.

### Claim 52

A pharmaceutical composition comprising therapeutically effective amount of an agent that modulates ATP production in the hypothalamus of an animal, wherein the composition is a medicament for treating an appetitive disease, disorder, or condition in an animal in need of such treatment, provided that said agent is not an extract from a plant of the genus Trichocaulon or Hoodia.

### Claim 53

(canceled)

### Claim 54

A pharmaceutical composition comprising therapeutically effective amount of an agent that increases ATP production or content in the hypothalamus of an animal, wherein the composition is a medicament for treating diabetes in an animal in need of such treatment, provided that said agent is not an extract from a plant of the genus Trichocaulon or Hoodia.

### Claim 55 (depends on 26)

The method of claim 26, wherein the metabolic disease, disorder, or condition is obesity.

### Claim 56 (depends on 55)

The pharmaceutical composition of claim 55, wherein the metabolic disease, disorder or condition is obesity.

### Claim 57 (depends on 26)

The method of claim 26, wherein the metabolic disease, disorder or condition is diabetes.

### Claim 58 (depends on 55)

The pharmaceutical composition of claim 55, wherein the metabolic disease, condition or disorder is diabetes.

### Claim 59 (depends on 49)

The method of claim 49, wherein the appetitive disease, disorder, or condition is obesity.

### Claim 60 (depends on 52)

The pharmaceutical composition of claim 52, wherein the appetitive disease, disorder or condition is obesity.
